$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000119312516679283 Filed on August 11, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.770M	$2.160M	$1.740M
YoY Change	-19.18%	24.14%	32.82%
% of Gross Profit
Research & Development	$4.880M	$5.794M	$5.858M
YoY Change	-16.55%	-1.09%	25.47%
% of Gross Profit
Depreciation & Amortization	$404.0K	$432.0K	$397.0K
YoY Change	-2.42%	8.82%	148.13%
% of Gross Profit
Operating Expenses	$6.648M	$7.955M	$7.593M
YoY Change	-17.3%	4.77%	26.34%
Operating Profit	-$6.648M	-$7.955M	-$7.593M
YoY Change	-17.3%	4.77%	26.34%
Interest Expense	$20.00K	$17.00K	$26.00K
YoY Change	-13.04%	-34.62%	-101.14%
% of Operating Profit
Other Income/Expense, Net	-$2.667M	-$83.00K	-$40.00K
YoY Change	6738.46%	107.5%	-98.25%
Pretax Income	-$9.320M	-$8.040M	-$7.630M
YoY Change	15.35%	5.37%	-8.07%
Income Tax
% Of Pretax Income
Net Earnings	-$9.315M	-$8.038M	-$7.633M
YoY Change	15.31%	5.31%	-8.06%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$42.36M	-$36.55M	-$34.68M
COMMON SHARES
Basic Shares Outstanding	13.27M shares	13.27M shares	0.000 shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.99M	$15.93M	$45.22M
YoY Change	0.72%	-64.77%	481.23%
Cash & Equivalents	$37.99M	$15.93M	$45.22M
Short-Term Investments
Other Short-Term Assets	$200.0K	$350.0K	$900.0K
YoY Change	-45.95%	-61.11%	-65.38%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$38.20M	$16.28M	$46.12M
YoY Change	0.28%	-64.71%	344.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.263M	$4.665M	$5.428M
YoY Change	-22.67%	-14.06%	151.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$140.0K	$140.0K	$1.180M
YoY Change	-88.24%	-88.14%	-31.79%
Total Long-Term Assets	$4.600M	$5.002M	$7.119M
YoY Change	-36.23%	-29.74%	59.62%
TOTAL ASSETS
Total Short-Term Assets	$38.20M	$16.28M	$46.12M
Total Long-Term Assets	$4.600M	$5.002M	$7.119M
Total Assets	$42.80M	$21.28M	$53.24M
YoY Change	-5.53%	-60.03%	258.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.665M	$1.769M	$2.337M
YoY Change	-16.79%	-24.3%	-18.0%
Accrued Expenses	$4.290M	$3.560M	$2.093M
YoY Change	75.17%	70.09%	24.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$580.0K	$580.0K	$580.0K
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$7.209M	$6.721M	$6.687M
YoY Change	7.76%	0.51%	10.35%
LONG-TERM LIABILITIES
Long-Term Debt	$320.0K	$470.0K	$1.050M
YoY Change	-64.84%	-55.24%
Other Long-Term Liabilities	$31.23M	$1.200M	$1.630M
YoY Change	1941.18%	-26.38%	-94.28%
Total Long-Term Liabilities	$31.55M	$1.670M	$2.680M
YoY Change	1193.03%	-37.69%	-90.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.209M	$6.721M	$6.687M
Total Long-Term Liabilities	$31.55M	$1.670M	$2.680M
Total Liabilities	$38.76M	$8.389M	$9.373M
YoY Change	324.76%	-10.5%	-72.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$190.8M	-$181.5M	-$149.1M
YoY Change	21.38%	21.71%
Common Stock	$194.9M	$194.4M	$193.0M
YoY Change	0.77%	0.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.036M	$12.89M	$43.87M
YoY Change
Total Liabilities & Shareholders Equity	$42.80M	$21.28M	$53.24M
YoY Change	-5.53%	-60.03%	258.75%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$9.315M	-$8.038M	-$7.633M
YoY Change	15.31%	5.31%	-8.06%
Depreciation, Depletion And Amortization	$404.0K	$432.0K	$397.0K
YoY Change	-2.42%	8.82%	148.13%
Cash From Operating Activities	-$5.460M	-$6.540M	-$7.470M
YoY Change	-20.64%	-12.45%	37.06%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$280.0K	-$400.0K
YoY Change	-98.0%	-30.0%	471.43%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.00K	-$280.0K	-$400.0K
YoY Change	-98.0%	-30.0%	471.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	27.53M	-140.0K	-90.00K
YoY Change	-23041.67%	55.56%	-100.91%
NET CHANGE
Cash From Operating Activities	-5.460M	-6.540M	-7.470M
Cash From Investing Activities	-10.00K	-280.0K	-400.0K
Cash From Financing Activities	27.53M	-140.0K	-90.00K
Net Change In Cash	22.06M	-6.960M	-7.960M
YoY Change	-394.13%	-12.56%	-280.09%
FREE CASH FLOW
Cash From Operating Activities	-$5.460M	-$6.540M	-$7.470M
Capital Expenditures	-$10.00K	-$280.0K	-$400.0K
Free Cash Flow	-$5.450M	-$6.260M	-$7.070M
YoY Change	-14.58%	-11.46%	31.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13274407	shares
CY2012Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	117000
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45222000
CY2015Q2	hsgx	Fair Value Input Amount Transfer Between Levels FairValueInputAmountTransferBetweenLevels	0
CY2016Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	13788000
CY2016Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	630000
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8851000
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13274407	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13274407	shares
CY2016Q2	us-gaap	Assets Assets	21278000
CY2016Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	384000
CY2016Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	131000
CY2016Q2	us-gaap	Assets Current AssetsCurrent	16276000
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	194277000
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15926000
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	133000
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1769000
CY2016Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	269000
CY2016Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	156138	shares
CY2016Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2288000
CY2016Q2	us-gaap	Loans Payable Current LoansPayableCurrent	583000
CY2016Q2	us-gaap	Noncurrent Assets NoncurrentAssets	4665000
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	430000
CY2016Q2	us-gaap	Liabilities Liabilities	8389000
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21278000
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	200000
CY2016Q2	us-gaap	Loans Payable LoansPayable	1053000
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6721000
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	178000
CY2016Q2	us-gaap	Incentive From Lessor IncentiveFromLessor	814000
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	292000
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	583000
CY2016Q2	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	407000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	56000
CY2016Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	470000
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4665000
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13516000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.16
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	12889000
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3120000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.75
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	310422	shares
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181521000
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	350000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	56000
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	53000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1235340	shares
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	137000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.82
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1344329	shares
CY2016Q2	hsgx	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	4.18
CY2016Q2	hsgx	Fair Value Input Amount Transfer Between Levels FairValueInputAmountTransferBetweenLevels	0
CY2016Q2	hsgx	Accrued Liability Current Excluding Lease Incentive Payable AccruedLiabilityCurrentExcludingLeaseIncentivePayable	1274000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58060000
CY2015Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	25764000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	630000
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7989000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13273470	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13273470	shares
CY2015Q4	us-gaap	Assets Assets	36786000
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	451000
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	126000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	31236000
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	193631000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30915000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	132000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2024000
CY2015Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	229000
CY2015Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	156138	shares
CY2015Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1546000
CY2015Q4	us-gaap	Loans Payable Current LoansPayableCurrent	583000
CY2015Q4	us-gaap	Noncurrent Assets NoncurrentAssets	5213000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	430000
CY2015Q4	us-gaap	Liabilities Liabilities	8588000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36786000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	200000
CY2015Q4	us-gaap	Loans Payable LoansPayable	1344000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6359000
CY2015Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	1017000
CY2015Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	407000
CY2015Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	761000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5213000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13202000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	28198000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.32
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165565000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	321000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	137000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1230838	shares
CY2015Q4	hsgx	Accrued Liability Current Excluding Lease Incentive Payable AccruedLiabilityCurrentExcludingLeaseIncentivePayable	1444000
CY2014Q4	hsgx	Class Of Warrant Or Right Number Of Securities Surrendered ClassOfWarrantOrRightNumberOfSecuritiesSurrendered	5839	shares
CY2012Q3	hsgx	Class Of Warrant Or Right Exercisable Expiration Period ClassOfWarrantOrRightExercisableExpirationPeriod	P10Y
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	15000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12838000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.18
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	492000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3844000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	647000
	us-gaap	Depreciation Depreciation	768000
	us-gaap	Sales Revenue Net SalesRevenueNet	0
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	591000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-131000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-43000
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	114000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1024000
	us-gaap	Operating Expenses OperatingExpenses	15466000
	us-gaap	Net Income Loss NetIncomeLoss	-15597000
	us-gaap	Interest Expense InterestExpense	88000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1320000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2663000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	101000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15466000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4637000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-467000
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	1434000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16155000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1320000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4738000
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	us-gaap	Repayments Of Debt RepaymentsOfDebt	114000
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P4Y11M23D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.646	pure
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0160	pure
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11622000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.643	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0164	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	492000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13208483	shares
	hsgx	Deferred Rent And Lease Incentive DeferredRentAndLeaseIncentive	60000
	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-15597000
	dei	Entity Registrant Name EntityRegistrantName	Histogenics Corporation
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14989000
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	40000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4373000
	us-gaap	Depreciation Depreciation	862000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Sales Revenue Net SalesRevenueNet	0
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	494000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-203000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-167000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-170000
	us-gaap	Operating Expenses OperatingExpenses	15753000
	us-gaap	Net Income Loss NetIncomeLoss	-15956000
	us-gaap	Interest Expense InterestExpense	36000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-314000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-255000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29000
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Reclassifications</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company has reclassified certain prior period amounts to conform to the current period presentation. The amounts reclassified impact Accounts Payable and Accrued Expenses and Accounts Payable due to Intrexon Corporation (“Intrexon”) and Accrued Expenses due to Intrexon Corporation for the six months ended June 30, 2015 and the year ended December 31, 2015.</p> </div>
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15753000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-291000
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	742000
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. NATURE OF BUSINESS</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Organization</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Histogenics Corporation (the “Company”) was incorporated under the laws of the Commonwealth of Massachusetts on June 28, 2000 and has its principal operations in Waltham, Massachusetts. In 2006, the Company’s board of directors approved a corporate reorganization pursuant to which the Company incorporated as a Delaware corporation. The Company is a regenerative medicine company engaged in developing and commercializing products in the musculoskeletal segment of the marketplace. The Company combines cell therapy and tissue engineering technologies to develop products for tissue repair and regeneration focusing on patients suffering from cartilage-derived pain and immobility. The Company is developing technology and products to reverse or prevent cartilage damage, including NeoCart for the repair of cartilage lesions. NeoCart is currently in a Phase 3 clinical trial in the United States under a special protocol assessment with the U.S. Food and Drug Administration (“FDA”) for the treatment of knee cartilage damage.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> On May 13, 2011, the Company completed the acquisition of ProChon Biotech Ltd. (“ProChon”), a privately-held biotechnology company focused on modulating the fibroblast growth factor system for consideration of $2,224 to enable it to create more effective solutions for tissue regeneration. ProChon’s products combine cell regeneration technologies with proprietary growth factors and biocompatible scaffolds to restore injured or chronically damaged tissues. The acquisition of ProChon provided the Company with access to a significant portfolio of intellectual property, including proprietary cell growth factors, in addition to furthering opportunities for the use of biomaterials to create more effective solutions for regenerating human tissue. The acquisition led to the initial recognition of goodwill, which was subsequently written off in 2011, and intangible assets including IPR&D and a licensing agreement which have been impaired as discussed in Note 2.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> On December 18, 2014, the Company formed a wholly owned subsidiary, Histogenics Securities Corporation, under the laws of the Commonwealth of Massachusetts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Since its inception, the Company has devoted substantially all of its efforts to product development, recruiting management and technical staff, raising capital, starting up production and building infrastructure and has not yet generated revenues from its planned principal operations. Expenses have primarily been for research and development and administrative costs.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company is subject to a number of risks. The developmental nature of its activities is such that significant inherent risks exist in the Company’s operations. Principal among these risks are the successful development of therapeutics, successfully enrolling patients in its clinical trials in a timely manner, ability to obtain adequate financing, obtaining regulatory approval for any of its product candidates in any jurisdiction, compliance with government regulations, protection of proprietary therapeutics, fluctuations in operating results, dependence on key personnel and collaborative partners, adoption of the Company’s products by the physician community, rapid technological changes inherent in the markets targeted, and substitute products and competition from larger companies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Liquidity</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company had an accumulated deficit at June 30, 2016 of $181.5 million and has incurred losses and cash flow deficits from operations for the six months ended June 30, 2016 and 2015. The Company has financed operations to date primarily through private placements of equity securities, the issuance of common stock in the initial public offering completed in December 2014, and borrowings under debt agreements. The Company anticipates that it will continue to incur net losses for the next several years and will require additional capital to complete the enrollment of the NeoCart clinical trial, and for the further development of its existing product candidates. The Company believes that its existing cash and cash equivalents will be sufficient to fund its projected cash needs into the first quarter of 2017. To meet its capital needs, the Company intends to raise additional capital through debt or equity financing or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The failure of the Company to obtain sufficient funds on commercially acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Basis of Accounting</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The condensed consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). However, they do not include all of the information and footnotes required by GAAP for complete financial statements. These interim condensed consolidated financial statements, in the opinion of the Company’s management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods ended June 30, 2016 and 2015. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2015, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 10, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The condensed consolidated financial statements include the accounts of Histogenics Corporation and its wholly-owned subsidiaries, ProChon and Histogenics Securities Corporation. All significant intercompany accounts and transactions are eliminated in consolidation.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14384000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	314000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	291000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	937	shares
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P7Y7D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	5.34
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.50
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.71
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.638	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.76
	dei	Trading Symbol TradingSymbol	HSGX
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0161	pure
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11380000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.596	pure
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	377000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	211340	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0140	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	96912	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	647000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13270531	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M6D
	hsgx	Deferred Rent And Lease Incentive DeferredRentAndLeaseIncentive	265000
	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-15956000
	hsgx	Period Of Contractual Agreement PeriodOfContractualAgreement	P18M
	hsgx	Contractual Agreement Month Year ContractualAgreementMonthYear	2016-05
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	257000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1735000
CY2015Q2	us-gaap	Depreciation Depreciation	397000
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	0
CY2015Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-40000
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	7593000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-7633000
CY2015Q2	us-gaap	Interest Expense InterestExpense	26000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7593000
CY2015Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P7Y8M23D
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2015Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.696	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0177	pure
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M7D
CY2015Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13215701	shares
CY2015Q2	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-7633000
CY2015Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0264	pure
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5858000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.596	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.88
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	336000
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2161000
CY2016Q2	us-gaap	Depreciation Depreciation	432000
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	0
CY2016Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	236000
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-83000
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-66000
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	7955000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-8038000
CY2016Q2	us-gaap	Interest Expense InterestExpense	17000
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7955000
CY2016Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y11M12D
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2016Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.629	pure
CY2016Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0156	pure
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5794000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.658	pure
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0135	pure
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2016Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13270433	shares
CY2016Q2	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-8038000

Files In Submission

Name	View Source	Status
0001193125-16-679283-index-headers.html	Edgar Link	pending
0001193125-16-679283-index.html	Edgar Link	pending
0001193125-16-679283.txt	Edgar Link	pending
0001193125-16-679283-xbrl.zip	Edgar Link	pending
d212966d10q.htm	Edgar Link	pending
d212966dex1033.htm	Edgar Link	pending
d212966dex311.htm	Edgar Link	pending
d212966dex312.htm	Edgar Link	pending
d212966dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hsgx-20160630.xml	Edgar Link	completed
hsgx-20160630.xsd	Edgar Link	pending
hsgx-20160630_cal.xml	Edgar Link	unprocessable
hsgx-20160630_def.xml	Edgar Link	unprocessable
hsgx-20160630_lab.xml	Edgar Link	unprocessable
hsgx-20160630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2016 Q3 Form 10-Q Financial Statement

#000119312516679283 Filed on August 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2016 Q3 Form 10-Q Financial Statement

#000119312516679283 Filed on August 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn